Roche Blood Cancer Medicine Fails to Show Major ImprovementBy
Success would have helped offset competition from biosimilars
Roche says it will continue to analyze Goya trial data
Swiss drugmaker Roche Holding AG said its blood cancer medicine Gazyva failed to show a significant improvement over its best-seller Rituxan, a setback in efforts to defend the aging blockbuster against copycats.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.